Skip to content
Review Open access

Reprogramming tumor-associated macrophages in breast cancer: from myeloid plasticity and tumor-promoting programs to CAR-macrophage therapy

Oct 2026 · Journal of Hematology & Oncology · Vol 19 · 0 citations · 207 references
Medicine

TL;DR

A translational roadmap integrating spatial biomarkers, quantitative target selection, macrophage-adapted CAR design, checkpoint-resistant phagocytosis, metabolic engineering, safety switches, and biomarker-guided combination therapy is proposed.

Abstract

Breast cancer develops within spatially organized, multicellular microenvironments in which particular tumor-associated macrophage (TAM) states can influence immune access and stromal remodeling. Conventional M1/M2 classification and total macrophage density fail to capture the developmental, transcriptional, metabolic, and spatial heterogeneity that determines TAM function. This macrophage-focused review examines breast cancer within its multicellular microenvironment, integrating lineage-tracing, single-cell, spatial, mechanistic, and clinical evidence while distinguishing breast-specific findings from hypotheses extrapolated from other tumors. We examine how tissue-resident and monocyte-derived macrophages are recruited, retained, expanded, and reprogrammed across primary and metastatic sites, emphasizing interactions with malignant cells, cancer-associated fibroblasts, extracellular matrix, vasculature, adipose tissue, and lymphoid populations. In defined breast-tumor contexts, TAM programs have been implicated in immune exclusion, invasion, metastatic dissemination, and adaptation to systemic treatment, although evidence strength varies across mechanisms and therapeutic modalities. Small and heterogeneous clinical studies have not established a benefit from broad CSF1/CSF1R-axis targeting in breast cancer, despite encouraging preclinical findings. Accordingly, we highlight a shift toward state-selective, spatially resolved, and temporally coordinated targeting. Emerging approaches include restoring phagocytosis, disrupting chemokine and fibrotic circuits, metabolic reprogramming, and converting suppressive TAMs into inflammatory, antigen-presenting effectors. A major focus is chimeric antigen receptor macrophage (CAR-M) therapy, which combines antigen-directed phagocytosis with tumor infiltration, matrix remodeling, antigen presentation, and recruitment of endogenous immunity. Although early clinical data support manufacturing feasibility, tumor trafficking, and acceptable initial safety, limited antitumor activity underscores challenges involving antigen heterogeneity, persistence, metabolic fitness, biodistribution, and scalable production. We propose a translational roadmap integrating spatial biomarkers, quantitative target selection, macrophage-adapted CAR design, checkpoint-resistant phagocytosis, metabolic engineering, safety switches, and biomarker-guided combination therapy. This framework positions macrophage reprogramming as a context-dependent strategy for modifying selected breast-tumor niches, with therapeutic targets chosen according to the macrophage program and its surrounding cellular architecture. Not applicable. Breast tumors contain spatially organized, multicellular niches in which macrophage functions depend on neighboring immune, stromal, vascular, and malignant cells. Single-cell and spatial profiling reveal diverse macrophage states that cannot be adequately represented by the conventional M1/M2 classification. Macrophage interactions with tumor cells, fibroblasts, extracellular matrix, vasculature, and lymphocytes regulate immune exclusion, invasion, and metastatic dissemination. Therapy-induced myeloid adaptation contributes to resistance to chemotherapy, radiotherapy, endocrine therapy, HER2-targeted treatment, and immune-checkpoint blockade. Broad macrophage-targeting has not established consistent clinical benefit in breast cancer; experimental studies also indicate that depletion can affect macrophage populations with protective functions. State-selective, spatially resolved, and temporally coordinated macrophage reprogramming may provide greater precision than indiscriminate myeloid-cell elimination. CAR-macrophage therapy integrates antigen-specific phagocytosis, tumor infiltration, matrix remodeling, antigen presentation, and activation of endogenous antitumor immunity.

Read PDF

Similar papers

Review 2026

Tumor-associated macrophages: Ontogeny, plasticity, spatial ecosystems, and therapeutic targeting.

This chapter provides an integrated framework for understanding TAM biology across multiple regulatory dimensions, including ontogeny, plasticity, metabolism, epigenetic control, and spatial niche organization, and synthesizes current and emerging therapeutic strategies targeting TAM recruitment, survival, reprogrammin...

A. Elnaggar, Abdelrahman Elnaggar · 0 citations
Review Open access Sep 2026

TREM2⁺ tumor-associated macrophages in cancer: context-dependent biology, biomarkers and precision immunotherapy.

A context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy is proposed.

Xue-Jun Guo, Jing-Ya Yu, Xiao-Yan Lin et al. · 1 citation
Review Open access Oct 2026

Tumor-associated macrophage reprogramming in cancer: recent advances in resistance mechanisms and therapy

Tumor-associated macrophages (TAMs) are abundant, heterogeneous, and spatially organized immune cells that regulate cancer progression, immune evasion, metastasis, and therapeutic resistance. Single-cell and spatial technologies have revealed diverse TAM states shaped by ontogeny, tumor type, disease stage, cytokines,...

Abdullah Farhan Saeed, M. Ashraf, Muhammad Iqbal · 0 citations
Review Open access Oct 2026

TUMOR MICROENVIRONMENT: EMERGING INSIGHTS INTO CANCER PROGRESSION AND THERAPEUTIC TARGETS - A NARRATIVE REVIEW

The tumor microenvironment (TME) is increasingly recognized as a dynamic and biologically active ecosystem that profoundly influences cancer initiation, progression, metastasis, immune escape, and therapeutic resistance. Rather than functioning as an isolated mass of malignant cells, a tumor consists of complex interac...

Drishti Singla, Sahil Singhal, Samanvaya Sharma et al. · 0 citations
Oct 2026

CXCL8⁺HIF-1α⁺ macrophages define a disease-associated myeloid state during colorectal tumorigenesis.

Tumor-associated myeloid alterations extend beyond the local microenvironment and involve systemic changes in myeloid development and circulating monocytes. However, how these systemic changes are coordinated with macrophage reprogramming during colorectal tumorigenesis remains unclear. Here, we identified coordinated...

Bao-Hui Song, Xu-Cheng Huo, Hao-Jun Li et al. · 0 citations
Open access Oct 2026

MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity

Cancer cell-intrinsic epithelial-mesenchymal plasticity (EMP) drives carcinoma progression through increased intratumoral heterogeneity and an immunosuppressive tumor microenvironment (TME). Specifically, EMP activation in murine mammary carcinomas results in exclusion of CD8+ T-cells and recruitment of immunosuppressi...

Kimaya M. Bakhle, Andreas Stephanou, Sarthak Sahoo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.